Pathophysiology of gadolinium-associated systemic fibrosis

Area of Science:

• Nephrology
• Radiology
• Pathology

Background:

• Systemic fibrosis is a severe condition associated with gadolinium-based contrast agents (GBCAs) used in magnetic resonance imaging.
• Clinical practice has been significantly impacted by litigation fears, despite the condition's rarity.
• Current understanding of gadolinium-associated systemic fibrosis (GASF) lacks experimental validation, relying heavily on case reports and unproven theories.

Purpose of the Study:

• To review and synthesize experimentally-derived information on the pathophysiology of gadolinium-associated systemic fibrosis.
• To elucidate the mechanisms by which gadolinium-containing contrast agents trigger systemic fibrosis.
• To understand the factors contributing to the chronicity of the disease.

Main Methods:

• Review of experimental studies investigating gadolinium toxicity and fibrosis.
• Analysis of in vitro and in vivo data related to gadolinium-based contrast agent mechanisms.
• Synthesis of findings from the authors' laboratory and other research groups.

Main Results:

• Experimental data provides insights into the pathophysiology of GASF, challenging existing conjectures.
• The review highlights the need for mechanistic understanding beyond correlation.
• Understanding the role of gadolinium ion properties and release in fibrosis development is crucial.

Conclusions:

• Experimental evidence is essential for understanding gadolinium-associated systemic fibrosis.
• Further research is needed to fully elucidate the mechanisms of GBCA-induced fibrosis.
• This review consolidates current experimental knowledge to guide future investigations.